Sign in
CompletedPhase 2

A Dose Finding Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects

Key facts

Who runs it
Innovent Biologics (Suzhou) Co. Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
84 people enrolled
Started
10 Jul 2024
Ended
9 Jan 2025
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Febuxostat
  • IBI128
Record updated
27 March 2025

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • Participants must be aged between 18 and 75 years old (inclusive, as of the time of signing the informed consent form), with no gender restrictions
  • Body Mass Index (BMI) should fall within the range of 18.0 to 40.0 kg/m² (including both ends of the range)
  • Subjects must meet the 2015 ACR/EULAR classification criteria for the diagnosis of gout (refer to Appendix 4)
  • At the screening stage, subjects must have a blood uric acid level of ≥480 μmol/L
  • Subjects must voluntarily sign the informed consent form and agree to strictly adhere to the requirements outlined in this protocol

Who cannot take part

  • Previous allergy or intolerance to Febuxostat
  • Subjects who have taken uric acid lowering medications within 2 weeks prior to screening
  • Subjects who experienced an acute gout flare-up within 4 weeks prior to screening or immediately before the first dose administration
  • History of allergy to any component of Tigulixostat
  • Subjects with a history of xanthinuria
  • Subjects considered to have secondary gout (elevated serum uric acid due to causes other than renal insufficiency)

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

IBI128 (Tigulixostat) is a novel non-purine selective inhibitor of xanthine oxidase (XO). The XO inhibitors lower uric acid concentrations in serum by inhibiting the production of uric acid.

Read full original descriptionShow less

This ia a randomized, open label, multicenter, parallel-group, positive-controlled, dose finding, and Phase II study to assess efficacy and safety of IBI128 in chinese gout subjects.

The 4 groups in the trial

  • Febuxostat 40mgExisting treatment, for comparison

    Tablets, Once a day (QD), Per oral

    Treatment: Febuxostat

  • IBI128 50mgTreatment being tested

    Tablets, Once a day (QD), Per oral

    Treatment: IBI128

  • IBI128 200mgTreatment being tested

    Tablets, Once a day (QD), Per oral

    Treatment: IBI128

  • IBI128 100mgTreatment being tested

    Tablets, Once a day (QD), Per oral

    Treatment: IBI128

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Open Label, Multicenter, Parallel-group, Positive-controlled, Dose Finding, and Phase II Study to Assess Efficacy and Safety of IBI128 in Chinese Gout Subjects
Record updated
27 March 2025